mobocertinib succinate

琥珀酸莫博赛替尼

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug Namemobocertinib succinate
Drug Alias NameMobocertinib莫博赛替尼EXKIVITY安卫力AP-32788 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR exon 20 insertion mutations inhibitors
TargetsEGFR exon 20 insertion mutations
Therapy Area/IndicationsRenal InsufficiencyHepatic InsufficiencyCarcinoma, Non-Small-Cell Lung +[4] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryUnited States
Original Approved Date2021/09/15
Country/TerritoryBelgiumCanadaUnited States +[27] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAriad Pharmaceuticals IncTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceuticals USA IncMillennium Pharmaceuticals IncTakeda Pharmaceutical Co Ltd +[5] 
Inactive CompaniesTakeda (China) International Trading Co Ltd
Active IndicationsRenal InsufficiencyHepatic InsufficiencyCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG